PapersFlow Research Brief
Peroxisome Proliferator-Activated Receptors
Research Guide
What is Peroxisome Proliferator-Activated Receptors?
Peroxisome Proliferator-Activated Receptors (PPARs) are a group of nuclear receptors that regulate metabolism, inflammation, lipid physiology, and transcriptional processes involved in metabolic diseases such as obesity and diabetes.
PPARs function as transcription factors activated by ligands like fatty acids and thiazolidinediones to control gene expression in lipid and glucose metabolism. The field encompasses 66,728 works with growth data unavailable over the past five years. Research highlights PPARγ's role as a high-affinity receptor for antidiabetic thiazolidinediones, promoting insulin sensitivity.
Topic Hierarchy
Research Sub-Topics
PPARγ in Adipose Tissue Metabolism
This sub-topic examines PPARγ's regulation of adipogenesis, lipid storage, and insulin sensitivity in adipocytes, including thiazolidinedione effects. Researchers study co-activator interactions and white/brown fat differentiation.
PPARα-Mediated Fatty Acid Oxidation
This sub-topic covers PPARα activation of hepatic and cardiac β-oxidation genes by fibrates and fatty acids in lipid homeostasis. Researchers investigate fasting responses and peroxisome proliferation pathways.
PPARs in Inflammation and Macrophage Polarization
This sub-topic explores PPARδ/γ suppression of pro-inflammatory cytokines and promotion of M2 macrophage phenotypes in atherosclerosis and obesity. Researchers analyze ligand effects on NF-κB signaling.
PPARβ/δ in Skeletal Muscle Energy Metabolism
This sub-topic studies PPARδ enhancement of mitochondrial biogenesis, fatty acid uptake, and endurance exercise adaptation in muscle fibers. Researchers test synthetic agonists for metabolic disorders.
Transcriptional Regulation by PPAR-RXR Heterodimers
This sub-topic investigates PPAR heterodimerization with RXR, PPRE binding, and co-regulator recruitment for target gene transactivation. Researchers map genome-wide binding and epigenetic modifications.
Why It Matters
PPARs influence treatments for type 2 diabetes and obesity through agonists like rosiglitazone and pioglitazone. "Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes" (Nissen and Wolski, 2007) reported rosiglitazone, a PPARγ agonist, associated with increased myocardial infarction risk. The PROactive Study in "Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial" (Dormandy et al., 2005) showed pioglitazone reduced macrovascular events in 5,238 patients with type 2 diabetes. "An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ)" (Lehmann et al., 1995) identified thiazolidinediones as direct PPARγ ligands, enabling insulin-sensitizing therapies despite cardiovascular concerns.
Reading Guide
Where to Start
"An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ)" (Lehmann et al., 1995) provides the foundational discovery of PPARγ as the target for thiazolidinedione antidiabetics, offering a clear entry to ligand-receptor basics.
Key Papers Explained
"An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ)" (Lehmann et al., 1995) identifies PPARγ's role in insulin sensitization, which Nissen and Wolski (2007) in "Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes" critiques for cardiovascular risks of such agonists. Dormandy et al. (2005) in "Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study" contrasts this by showing pioglitazone benefits. Xu et al. (2003) in "Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance" connects PPAR-regulated metabolism to inflammation.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Clinical trials on PPAR agonists like rosiglitazone and pioglitazone highlight unresolved tensions between metabolic benefits and cardiovascular safety, with no recent preprints or news to indicate shifts.
Papers at a Glance
Frequently Asked Questions
What is the role of PPARγ in antidiabetic therapy?
PPARγ binds thiazolidinedione antidiabetic agents with high affinity to promote adipocyte differentiation and insulin sensitivity in non-insulin-dependent diabetes models. "An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ)" (Lehmann et al., 1995) demonstrated this ligand-receptor interaction in vitro. These agents increase insulin action in peripheral tissues.
How do PPAR agonists like rosiglitazone affect cardiovascular risk?
Rosiglitazone, a PPARγ agonist, links to higher myocardial infarction risk and borderline increased death from cardiovascular causes. "Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes" (Nissen and Wolski, 2007) analyzed meta-data from trials showing this association. Limitations included lack of original time-to-event data.
What evidence connects PPARs to obesity-related insulin resistance?
Chronic inflammation in adipose tissue drives obesity-linked insulin resistance, with PPARs implicated in metabolic regulation. "Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance" (Xu et al., 2003) established causative links from human and animal studies. PPAR modulation influences lipid homeostasis and inflammation.
What did the PROactive Study reveal about pioglitazone?
Pioglitazone, a PPARγ agonist, provided secondary prevention of macrovascular events in type 2 diabetes patients. "Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial" (Dormandy et al., 2005) was a randomized trial in over 5,000 patients. It demonstrated reduced events compared to placebo.
How do PPARs relate to lipid synthesis regulation?
PPARs interact with pathways like SREBPs in cholesterol and fatty acid synthesis. "SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver" (Horton et al., 2002) describes SREBPs activating over 30 genes, with PPARs contributing to lipid homeostasis. This overlaps with PPAR functions in metabolism.
Open Research Questions
- ? How do cardiovascular risks of PPARγ agonists like rosiglitazone balance their insulin-sensitizing benefits in diabetes patients?
- ? What mechanisms link PPAR activation to adipose inflammation and insulin resistance in obesity?
- ? Can PPAR ligands improve macrovascular outcomes without increasing infarction risk, as seen in pioglitazone trials?
- ? How do PPARs integrate with SREBP pathways to fine-tune hepatic lipid synthesis under varying nutritional states?
Recent Trends
The field maintains 66,728 works with five-year growth data unavailable; no preprints from the last six months or news from the past year report changes.
Established papers like Lehmann et al. (1995, 3612 citations) and Nissen and Wolski (2007, 4623 citations) continue to shape understanding of PPARγ ligands.
Research Peroxisome Proliferator-Activated Receptors with AI
PapersFlow provides specialized AI tools for Biochemistry, Genetics and Molecular Biology researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Peroxisome Proliferator-Activated Receptors with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Biochemistry, Genetics and Molecular Biology researchers